Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Canopy Growth Corporation (WEED.TO)
CAD1.35
+0.01 (+0.75%)
CA TSX Healthcare Drug Manufacturers - Specialty & Generic
Address
1 Hershey Drive K7A 0A8
Smiths Falls, ON, CA
Smiths Falls, ON, CA
CEO
Luc Mongeau
Website
canopygrowth.com
IPO
2010-08-17
ISIN CA1380357048
Also trades on
NASDAQ Global Select · CGC (USD)
Toronto Stock Exchange · WEED.TO (CAD)
Description
Canopy Growth Corporation, through its various operating units, is actively involved in the cultivation, marketing, and distribution of cannabis and hemp-derived products. These offerings serve both recreational consumers and medical patients across key markets including Canada, the United States, and Germany. The company's business activities are structured into two main divisions: its global cannabis operations and its diverse portfolio of other consumer goods. Its extensive product line features dried cannabis flower, a variety of extracts and concentrates, beverages, edible gummies, and vaporization products. Canopy Growth commercializes these goods under numerous well-known brands such as Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra. Formed in 2009, the enterprise initially operated as Tweed Marijuana Inc. before adopting its current name, Canopy Growth Corporation, in September 2015. Its principal office is located in Smiths Falls, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CAD1.35
+0.01 (+0.75%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.42
Float Shares
178.60M
Free Float %
98.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.42% | -2.80% | -2.11% | -1.42% | -39.57% | -10.90% | -29.44% | -83.84% | -99.53% | -94.67% | -7.33% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (22 ratings, all time)
Buy
Price Targets & DCF
Current price
1.35
Ratings Trend (MoM)
38% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | +1 |
| Hold | 4 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
-13.56
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5.8% Q1'26: +9.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+100.0% ★ Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-74.4% Q1'26: -27.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-79.0% Q1'26: -204.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-36.7% Q1'26: -94.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-100.0% ★ Q1'26: -100.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.48× Q1'26: -0.51× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 5 EPS Ana. |
Mar 2027 5 Rev. Ana. 5 EPS Ana. |
Mar 2028 4 Rev. Ana. 5 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
922.6K
est.
|
12.70M
est: 9.40M (+35.1%)
|
39.90M
est: 31.34M (+27.3%)
|
77.95M
est: 61.34M (+27.1%)
|
226.34M
est: 169.76M (+33.3%)
|
398.77M
est: 296.68M (+34.4%)
|
546.65M
est: 439.45M (+24.4%)
|
475.70M
est: 431.05M (+10.4%)
|
333.25M
est: 314.64M (+5.9%)
|
297.15M
est: 209.99M (+41.5%)
|
269.00M
est: 193.74M (+38.8%)
|
205.05M
202.90M – 208.18M
+5.8% YoY
|
249.31M
240.72M – 259.63M
+21.6% YoY
|
277.46M
277.18M – 277.75M
+11.3% YoY
|
301.46M
301.21M – 301.70M
+8.6% YoY
|
328.49M
317.16M – 342.08M
+9.0% YoY
|
| EBITDA |
-757.3K
est.
|
938.0K
est: -7.71M (+112.2%)
|
-650.0K
est: -25.72M (+97.5%)
|
-30.19M
est: -50.34M (+40.0%)
|
-642.58M
est: -139.34M (-361.2%)
|
-1.38B
est: -243.50M (-465.6%)
|
-1.55B
est: -360.68M (-329.3%)
|
-52.98M
est: -353.79M (+85.0%)
|
-2.88B
est: -258.25M (-1,015.2%)
|
-312.83M
est: -172.67M (-81.2%)
|
-479.31M
est: -159.31M (-200.9%)
|
-168.60M
-171.18M – -166.84M
-5.8% YoY
|
-205.00M
-213.49M – -197.94M
-21.6% YoY
|
-228.15M
-228.38M – -227.92M
-11.3% YoY
|
-247.88M
-248.08M – -247.68M
-8.6% YoY
|
-270.11M
-281.29M – -260.80M
-9.0% YoY
|
| EBIT |
-797.4K
est.
|
-1.32M
est: -8.12M (+83.8%)
|
-6.71M
est: -27.08M (+75.2%)
|
-50.67M
est: -53.01M (+4.4%)
|
-689.50M
est: -146.72M (-370.0%)
|
-1.50B
est: -256.40M (-485.9%)
|
-1.68B
est: -379.79M (-341.2%)
|
-163.92M
est: -372.53M (+56.0%)
|
-2.96B
est: -271.93M (-988.5%)
|
-366.00M
est: -182.46M (-100.6%)
|
-522.43M
est: -168.34M (-210.3%)
|
-178.17M
-180.89M – -176.30M
-5.8% YoY
|
-216.63M
-225.60M – -209.16M
-21.6% YoY
|
-241.09M
-241.34M – -240.85M
-11.3% YoY
|
-261.94M
-262.15M – -261.73M
-8.6% YoY
|
-285.43M
-297.24M – -275.59M
-9.0% YoY
|
| Net Income |
-149.80M
est.
|
-3.50M
est: -115.68M (+97.0%)
|
-7.52M
est: -12.09M (+37.8%)
|
-67.28M
est: -213.18M (+68.4%)
|
-736.28M
est: -1.26B (+41.6%)
|
-1.32B
est: -4.36B (+69.7%)
|
-1.74B
est: -2.65B (+34.2%)
|
-310.04M
est: 413.65M (-175.0%)
|
-3.28B
est: -4.78B (+31.4%)
|
-657.27M
est: -588.77M (-11.6%)
|
-598.12M
est: -359.70M (-66.3%)
|
-36.75M
-42.00M – -31.50M
+89.8% YoY
|
-24.92M
-41.17M – -8.67M
+32.2% YoY
|
-23.91M
-42.42M – -5.40M
+4.1% YoY
|
-2.31M
-2.44M – -2.21M
+90.3% YoY
|
2.31M
2.21M – 2.44M
+200.0% YoY
|
| SGA |
665.2K
est.
|
17.33M
est: 6.78M (+155.7%)
|
38.55M
est: 22.59M (+70.6%)
|
131.13M
est: 44.22M (+196.5%)
|
605.83M
est: 122.39M (+395.0%)
|
867.74M
est: 213.89M (+305.7%)
|
523.85M
est: 316.82M (+65.3%)
|
361.10M
est: 310.76M (+16.2%)
|
297.98M
est: 226.84M (+31.4%)
|
175.98M
est: 153.55M (+14.6%)
|
121.71M
est: 141.67M (-14.1%)
|
149.94M
148.37M – 152.23M
+5.8% YoY
|
182.31M
176.02M – 189.85M
+21.6% YoY
|
202.89M
202.69M – 203.10M
+11.3% YoY
|
220.44M
220.26M – 220.61M
+8.6% YoY
|
240.21M
231.92M – 250.15M
+9.0% YoY
|
| EPS |
-1.39
est.
|
-0.05
est: -1.08 (+95.8%)
|
-0.14
est: -0.11 (-24.6%)
|
-0.31
est: -1.98 (+84.4%)
|
-1.99
est: -11.72 (+83.0%)
|
-3.89
est: -40.57 (+90.4%)
|
-4.38
est: -24.65 (+82.2%)
|
-0.81
est: 3.85 (-121.1%)
|
-12.18
est: -44.43 (+72.6%)
|
-8.79
est: -5.45 (-61.3%)
|
-5.56
est: -3.33 (-67.0%)
|
-0.33
-0.39 – -0.29
+90.1% YoY
|
-0.17
-0.38 – -0.08
+47.8% YoY
|
-0.14
-0.39 – -0.05
+17.4% YoY
|
-0.02
-0.02 – -0.02
+84.8% YoY
|
0.02
0.02 – 0.02
+200.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-06-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-06-10 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-06-09 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-06-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-06-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-06-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-06-03 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-06-02 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-06-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-82.95M
OE per share TTM
-0.44
Owner's Yield
-17.27%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
223.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 6 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares S&P/TSX SmallCap Index ETF XCS.TO | 0.19% | 329.2K | 0.60% |
| 2 | Lazard US Systematic Small Cap Equity ETF SYZ | 0.15% | 77.6K | 0.74% |
| 3 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 134.1K | 0.40% |
| 4 | TD Canadian Equity Index ETF TTP.TO | 0.01% | 445.1K | 0.05% |
| 5 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 79.6K | 0.22% |
| 6 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 20.9K | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-218.4K
Shares Outstanding
181.74M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Luc Mongeau | Chief Executive Officer & Director | 1M | male |
| Christelle Gedeon | Chief Business Development & Corporate Affairs Officer | 811.9K | — |
| Thomas Carlton Stewart | Chief Accounting Officer & Chief Financial Officer | 474.7K | male |
| Jason Green | Head of Agriculture - Hemp Division | — | — |
| Jurgen Bickel | MD and Co-Founder of STORZ & BICKEL GmbH | — | male |
| Michael Perron | Chief Operating Officer | — | male |
| Miles Worne | Managing Director of European Markets | — | male |
| Andrew Bevan | Senior Vice President of Medical Sales | — | male |
| Tyler Burns | Director of Investor Relations | — | male |
| Chrissy McHardy | Senior Vice President of Human Resources | — | female |
| David Manner | Managing Director of Storz & Bickel GmbH | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WEED.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
